Cannabis Biotech conducts cutting edge research to develop innovative cannabinoid products and therapies for the treatment of diseases and their symptoms including HIV, cancer, glaucoma and neurological disorders.
An increasing number of states in the U.S. and numerous countries have legalized or recognized the use of cannabinoid products and treatments, changing public attitudes as science demonstrates the benefits for the products in the management of certain diseases and conditions.
Headquartered in Ft. Lauderdale, Florida, Cannabis Biotech is led by Ron Leyland, who has demonstrated ability to identify trends, generate new products, produce and develop branding for individual products and product lines, create innovative sales and distribution strategies domestically and internationally, while maintaining the highest standards.
The mission of Cannabis Biotech is to be the leading firm which identifies and develops innovative cannabis-based solutions for patient-centered medical needs through scientific technologies involving standardization, production, extraction and delivery of cannabinoid medical products.
The Cannabis Biotech team is comprised of highly skilled professionals and scientists who have distinguished themselves in their fields. The Cannabis team will work with the world’s leading experts to acquire, assess and develop leading edge products and technologies. The company’s research and development component has a passion for the health and well-being of the patients who will benefit from the Cannabis Biotech products and therapies. Operating with integrity is part of the company culture.
Ron Leyland, President and CEO
As president and chief executive officer for Puget Technologies, Ron Leyland is not only responsible for guiding the overall direction of the company and implementing its mission and vision, but also for driving strategic opportunities for growth and increasing shareholder value.
Prior to joining Puget, Ron founded and led Nexagen USA in 2002. Leveraging the company’s successful launch of its initial proprietary product, the Jen Fe Diet Patch, he assembled an expert research and development team which went on to develop a well-accepted product line. The products consisted of patches, pills, lotions and drinks utilizing multiple delivery systems.
The success of Nexagen USA led to the formation of NexEurope. To support global expansion, Ron assembled and led an exceptionally talented international team to navigate the complex process of exporting products and establishing a local presence in multiple countries. Ron used his familiarity with local customs, culture and regulations to create an efficient operation throughout the multi-national region.
During this time, Ron created additional successful corporations to conduct neutraceutical research and development and to provide credit card payment solutions. Another vertically integrated operation developed by Ron was a shared service provider to support the other companies with IT development, customer and logistical support.
Previously, Ron founded USA Cellular LLC., which gained top position and shattered corporate sales records for years to follow.
Cannabis Biotech places the health and well-being of consumers first and resolves to be an ethical leader in the industry. As we concentrate on our mission we remain aware of our responsibility to our shareholders, employees, professionals who will dispense our products and the consumers who will benefit from them.